BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Dickson RC, Everhart JE, Lake JR, Wei Y, Seaberg EC, Wiesner RH, Zetterman RK, Pruett TL, Ishitani MB, Hoofnagle JH. Transmission of hepatitis B by transplantation of livers from donors positive for antibody to hepatitis B core antigen. The National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database. Gastroenterology 1997;113:1668-74. [PMID: 9352871 DOI: 10.1053/gast.1997.v113.pm9352871] [Cited by in Crossref: 315] [Cited by in F6Publishing: 276] [Article Influence: 12.6] [Reference Citation Analysis]
Number Citing Articles
1 Morillas RM, López Sisamón D. Reactivación de la hepatitis B asociada a agentes inmunodepresores y a quimioterapia. Historia natural, factores de riesgo y recomendaciones para prevenirla. Medicina Clínica 2019;152:107-14. [DOI: 10.1016/j.medcli.2018.08.018] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
2 Lown RN, Shaw BE. Beating the odds: factors implicated in the speed and availability of unrelated haematopoietic cell donor provision. Bone Marrow Transplant 2013;48:210-9. [DOI: 10.1038/bmt.2012.54] [Cited by in Crossref: 36] [Cited by in F6Publishing: 30] [Article Influence: 3.6] [Reference Citation Analysis]
3 Domen RE, Yen-lieberman B, Nelson KA, Chua J, Sholtis W, Tyus H, Isada CM. Use of an HBV-DNA Hybridization Assay in the Evaluation of Equivocal Hepatitis B Virus Tests in Solid Organ Donors. Prog Transpl 2000;10:42-6. [DOI: 10.1177/152692480001000108] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
4 Yamashiki N, Yoshizawa A, Ueda Y, Kaido T, Okajima H, Marusawa H, Seno H, Uemoto S. The use of hepatitis B immunoglobulin with or without hepatitis B vaccine to prevent de novo hepatitis B in pediatric recipients of anti-HBc-positive livers. Pediatr Transplant 2018;22:e13227. [PMID: 29761899 DOI: 10.1111/petr.13227] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
5 Campos Franco J, Otero Antón E, González Quintela A, Aguilera Guirao A, Varo Pérez E. Hepatitis B de novo con anticuerpo frente al HBcAg negativo en un trasplantado hepático. Gastroenterología y Hepatología 2004;27:51-4. [DOI: 10.1016/s0210-5705(03)79086-4] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
6 Patel SS, Leung DH. Hepatitis B immunity in the pediatric liver transplant population. Curr Opin Pediatr 2016;28:653-8. [PMID: 27367054 DOI: 10.1097/MOP.0000000000000391] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
7 Izmirli S, Celik DG, Yuksel P, Saribas S, Aslan M, Ergin S, Bahar H, Sen S, Cakal B, Oner A. The detection of occult HBV infection in patients with HBsAg negative pattern by real-time PCR method. Transfus Apher Sci. 2012;47:283-287. [PMID: 23021041 DOI: 10.1016/j.transci.2012.07.009] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
8 Pan JJ, Oh SH, Soldevila-Pico C, Nelson DR, Liu C. Low prevalence of HBV DNA in the liver allograft from anti-HBc-positive donors: a single-center experience. Clin Transplant 2011;25:164-70. [PMID: 20156222 DOI: 10.1111/j.1399-0012.2010.01211.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
9 Challine D, Chevaliez S, Pawlotsky JM. Efficacy of serologic marker screening in identifying hepatitis B virus infection in organ, tissue, and cell donors. Gastroenterology 2008;135:1185-91. [PMID: 18694749 DOI: 10.1053/j.gastro.2008.07.011] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]
10 Fabrizi F, Bunnapradist S, Lunghi G, Villa M, Martin P. Transplanting Solid Organs from HBsAg Negative Donors Positive for Antibody to Hepatitis B Core Antigen: The Implications. The International Journal of Artificial Organs 2018;26:972-83. [DOI: 10.1177/039139880302601102] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
11 Busuttil RW, Tanaka K. The utility of marginal donors in liver transplantation. Liver Transpl. 2003;9:651-663. [PMID: 12827549 DOI: 10.1053/jlts.2003.50105] [Cited by in Crossref: 494] [Cited by in F6Publishing: 424] [Article Influence: 26.0] [Reference Citation Analysis]
12 Kawai S, Yokosuka O, Imazeki F, Maru Y, Saisho H. State of HBV DNA in HBsAg-negative, anti-HCV-positive hepatocellular carcinoma: existence of HBV DNA possibly as nonintegrated form with analysis by Alu-HBV DNA PCR and conventional HBV PCR. J Med Virol. 2001;64:410-418. [PMID: 11468724 DOI: 10.1002/jmv.1066] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 0.6] [Reference Citation Analysis]
13 Owusu-Ofori S, Temple J, Sarkodie F, Anokwa M, Candotti D, Allain JP. Predonation screening of blood donors with rapid tests: implementation and efficacy of a novel approach to blood safety in resource-poor settings. Transfusion 2005;45:133-40. [PMID: 15660820 DOI: 10.1111/j.1537-2995.2004.04279.x] [Cited by in Crossref: 96] [Cited by in F6Publishing: 92] [Article Influence: 5.6] [Reference Citation Analysis]
14 Keeffe EB. Liver transplantation at the millennium. Past, present, and future. Clin Liver Dis. 2000;4:241-255. [PMID: 11232187 DOI: 10.1016/s1089-3261(05)70106-9] [Cited by in Crossref: 16] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
15 Umeda M, Marusawa H, Seno H, Katsurada A, Nabeshima M, Egawa H, Uemoto S, Inomata Y, Tanaka K, Chiba T. Hepatitis B virus infection in lymphatic tissues in inactive hepatitis B carriers. J Hepatol. 2005;42:806-812. [PMID: 15885350 DOI: 10.1016/j.jhep.2005.01.016] [Cited by in Crossref: 47] [Cited by in F6Publishing: 41] [Article Influence: 2.8] [Reference Citation Analysis]
16 Chotiyaputta W, Pelletier SJ, Fontana RJ, Lok AS. Long-term efficacy of nucleoside monotherapy in preventing HBV infection in HBsAg-negative recipients of anti-HBc-positive donor livers. Hepatol Int 2010;4:707-15. [PMID: 21286341 DOI: 10.1007/s12072-010-9188-0] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
17 Zhuge S, Ge C, Yang Y, Cui Y, Yue X, Zhang Z, Xu H, Huang A, Zhao Y. The prevalence of occult HBV infection in immunized children with HBsAg-positive parents: a hospital-based analysis. Hepatol Int 2020;14:503-12. [PMID: 32472310 DOI: 10.1007/s12072-020-10055-9] [Reference Citation Analysis]
18 Terrault N, Roche B, Samuel D. Management of the hepatitis B virus in the liver transplantation setting: A European and an American perspective. Liver Transpl 2005;11:716-32. [DOI: 10.1002/lt.20492] [Cited by in Crossref: 127] [Cited by in F6Publishing: 104] [Article Influence: 7.5] [Reference Citation Analysis]
19 Hollinger FB, Sood G. Occult hepatitis B virus infection: a covert operation. J Viral Hepat. 2010;17:1-15. [PMID: 20002296 DOI: 10.1111/j.1365-2893.2009.01245.x] [Cited by in Crossref: 110] [Cited by in F6Publishing: 113] [Article Influence: 8.5] [Reference Citation Analysis]
20 Rizzetto M. Editorial: Transmission of hepatitis B infection from hepatitis B core antibody—positive livers: Background and prevention. Liver Transplantation 2001;7:518-20. [DOI: 10.1053/jlts.2001.25880] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
21 Das S, Sarker S, Ghorashi SA, Forwood JK, Raidal SR. A comparison of PCR assays for beak and feather disease virus and high resolution melt (HRM) curve analysis of replicase associated protein and capsid genes. J Virol Methods 2016;237:47-57. [PMID: 27565820 DOI: 10.1016/j.jviromet.2016.08.015] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
22 Shetty K, Hussain M, Nei L, Reddy KR, Lok AS. Prevalence and significance of occult hepatitis B in a liver transplant population with chronic hepatitis C. Liver Transpl. 2008;14:534-540. [PMID: 18324677 DOI: 10.1002/lt.21284] [Cited by in Crossref: 45] [Cited by in F6Publishing: 45] [Article Influence: 3.2] [Reference Citation Analysis]
23 Millar AJW, Spearman W, Mcculloch M, Goddard E, Raad J, Rode H, Kahn D, Cywes S. Liver transplantation for children - the Red Cross Children's Hospital experience. Pediatric Transplantation 2004;8:136-44. [DOI: 10.1046/j.1399-3046.2003.00131.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
24 Castells L. [Viral hepatitides infections in transplant recipients]. Enferm Infecc Microbiol Clin 2006;24:118-28. [PMID: 16545319 DOI: 10.1157/13085018] [Reference Citation Analysis]
25 Segovia R, Sánchez-Fueyo A, Rimola A, Grande L, Bruguera M, Costa J, Soguero C, Uriz J. Evidence of serious graft damage induced by de novo hepatitis B virus infection after liver transplantation. Liver Transpl 2001;7:106-12. [PMID: 11172393 DOI: 10.1053/jlts.2001.21457] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 1.3] [Reference Citation Analysis]
26 Tamori A, Nishiguchi S, Kubo S, Narimatsu T, Habu D, Takeda T, Hirohashi K, Shiomi S. HBV DNA integration and HBV-transcript expression in non-B, non-C hepatocellular carcinoma in Japan. J Med Virol. 2003;71:492-498. [PMID: 14556260 DOI: 10.1002/jmv.10514] [Cited by in Crossref: 32] [Cited by in F6Publishing: 34] [Article Influence: 1.8] [Reference Citation Analysis]
27 Palmore TN, Shah NL, Loomba R, Borg BB, Lopatin U, Feld JJ, Khokhar F, Lutchman G, Kleiner DE, Young NS, Childs R, Barrett AJ, Liang TJ, Hoofnagle JH, Heller T. Reactivation of hepatitis B with reappearance of hepatitis B surface antigen after chemotherapy and immunosuppression. Clin Gastroenterol Hepatol 2009;7:1130-7. [PMID: 19577007 DOI: 10.1016/j.cgh.2009.06.027] [Cited by in Crossref: 45] [Cited by in F6Publishing: 47] [Article Influence: 3.5] [Reference Citation Analysis]
28 Mutimer D. Review article: hepatitis B and liver transplantation. Aliment Pharmacol Ther 2006;23:1031-41. [DOI: 10.1111/j.1365-2036.2006.02855.x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 18] [Article Influence: 1.6] [Reference Citation Analysis]
29 Myers RP, Thibault V, Poynard T. The impact of prior hepatitis B virus infection on liver histology and the response to interferon therapy in chronic hepatitis C. J Viral Hepat. 2003;10:103-110. [PMID: 12614466 DOI: 10.1046/j.1365-2893.2003.00407.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
30 Chamorro C, Aparicio M. Influence of anti-HBc positive organ donor in lung donor selection. Arch Bronconeumol 2012;48:320-4. [PMID: 22709511 DOI: 10.1016/j.arbres.2012.04.025] [Reference Citation Analysis]
31 Horlander JC, Boyle N, Manam R, Schenk M, Herring S, Kwo PY, Lumeng L, Chalasani N. Vaccination against Hepatitis B in Patients with Chronic Liver Disease Awaiting Liver Transplantation: . The American Journal of the Medical Sciences 1999;318:304. [DOI: 10.1097/00000441-199911000-00004] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 1.1] [Reference Citation Analysis]
32 Lei M, Yan LN, Yang JY, Wen TF, Li B, Wang WT, Wu H, Xu MQ, Chen ZY, Wei YG. Safety of hepatitis B virus core antibody-positive grafts in liver transplantation: A single-center experience in China. World J Gastroenterol 2018; 24(48): 5525-5536 [PMID: 30622380 DOI: 10.3748/wjg.v24.i48.5525] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
33 Onozawa M, Hashino S, Darmanin S, Okada K, Morita R, Takahata M, Shigematsu A, Kahata K, Kondo T, Tanaka J, Imamura M, Asaka M. HB vaccination in the prevention of viral reactivation in allogeneic hematopoietic stem cell transplantation recipients with previous HBV infection. Biol Blood Marrow Transplant 2008;14:1226-30. [PMID: 18940676 DOI: 10.1016/j.bbmt.2008.08.007] [Cited by in Crossref: 35] [Cited by in F6Publishing: 31] [Article Influence: 2.5] [Reference Citation Analysis]
34 Bárcena Marugán R, García Garzón S, López San Román A, Peña González E, García Plaza A, Nash R, Férnandez Muñoza R, Mateosa M. Riesgo de transmisión del virus de la hepatitis B de donantes de hígado anti-HBc positivos. Medicina Clínica 2001;116:125-8. [DOI: 10.1016/s0025-7753(01)71746-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
35 Prieto M. Antibody to hepatitis B core antigen-positive grafts: Not perfect but no longer marginal: Editorial. Liver Transpl 2009;15:1164-8. [DOI: 10.1002/lt.21814] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
36 Roche B, Samuel D. Treatment of hepatitis B and C after liver transplantation. Part 1, hepatitis B. Transplant Int 2004;17:746-58. [DOI: 10.1111/j.1432-2277.2004.tb00507.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
37 Varaklioti A, Kouramba A, Ioannidou P, Katsarou O. Occult hepatitis B virus infection in Greek patients with congenital bleeding disorders. Infect Genet Evol 2017;54:397-401. [PMID: 28705716 DOI: 10.1016/j.meegid.2017.07.012] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
38 Lledó JL, Fernández C, Gutiérrez ML, Ocaña S. Management of occult hepatitis B virus infection: An update for the clinician. World J Gastroenterol 2011; 17(12): 1563-1568 [PMID: 21472122 DOI: 10.3748/wjg.v17.i12.1563] [Cited by in CrossRef: 30] [Cited by in F6Publishing: 32] [Article Influence: 2.7] [Reference Citation Analysis]
39 Matsui T, Hayashi S, Tanaka Y. Is it necessary to revise the liver transplantation guidelines to meet the current situation? Hepatol Res 2021;51:1177-8. [PMID: 34850498 DOI: 10.1111/hepr.13710] [Reference Citation Analysis]
40 Siddiqui F, Mutchnick M, Kinzie J, Peleman R, Naylor P, Ehrinpreis M. Prevalence of hepatitis A virus and hepatitis B virus immunity in patients with polymerase chain reaction-confirmed hepatitis C: implications for vaccination strategy. Am J Gastroenterol. 2001;96:858-863. [PMID: 11280565 DOI: 10.1111/j.1572-0241.2001.03633.x] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 1.8] [Reference Citation Analysis]
41 Keeffe EB. Impact of organ shortage on liver transplantation: . Current Opinion in Organ Transplantation 2001;6:103-6. [DOI: 10.1097/00075200-200106000-00001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
42 Jain A, Orloff M, Abt P, Kashyap R, Mohanka R, Lansing K, Kelley M, Bozorgzadeh A. Use of hepatitis B core antibody-positive liver allograft in hepatitis C virus-positive and -negative recipients with use of short course of hepatitis B immunoglobulin and Lamivudine. Transplant Proc. 2005;37:3187-3189. [PMID: 16213345 DOI: 10.1016/j.transproceed.2005.07.049] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 1.4] [Reference Citation Analysis]
43 Donataccio D, Roggen F, De Reyck C, Verbaandert C, Bodeus M, Lerut J. Use of anti-HBc positive allografts in adult liver transplantation: toward a safer way to expand the donor pool. Transpl Int. 2006;19:38-43. [PMID: 16359375 DOI: 10.1111/j.1432-2277.2005.00225.x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 1.9] [Reference Citation Analysis]
44 Ersoy O, Yilmaz R, Arici M, Turgan C, Bayraktar Y. Prevalence of Occult Hepatitis B Infection in Hemodialysis Patients. Dial Transplant 2008;37:362-8. [DOI: 10.1002/dat.20258] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
45 Sokal EM, Paganelli M, Wirth S, Socha P, Vajro P, Lacaille F, Kelly D, Mieli-vergani G. Management of chronic hepatitis B in childhood: ESPGHAN clinical practice guidelines. Journal of Hepatology 2013;59:814-29. [DOI: 10.1016/j.jhep.2013.05.016] [Cited by in Crossref: 121] [Cited by in F6Publishing: 100] [Article Influence: 13.4] [Reference Citation Analysis]
46 Fontana R. Are we ready for marginal hepatitis B core antibody-positive living liver donors? Liver Transplantation 2003;9:833-6. [DOI: 10.1053/jlts.2003.50141] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
47 Udayakumar VP, Surendran S, Padma UD. Utilization of hepatitis B core antibody positive grafts in living donor liver transplantation. Indian J Gastroenterol 2018;37:39-43. [PMID: 29450703 DOI: 10.1007/s12664-018-0823-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
48 Umeda M, Marusawa H, Ueda M, Takada Y, Egawa H, Uemoto S, Chiba T. Beneficial effects of short-term lamivudine treatment for de novo hepatitis B virus reactivation after liver transplantation. Am J Transplant 2006;6:2680-5. [PMID: 17049057 DOI: 10.1111/j.1600-6143.2006.01542.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
49 Chamorro C, Aparicio M. Influence of Anti-HBc Positive Organ Donor in Lung Donor Selection. Archivos de Bronconeumología (English Edition) 2012;48:320-4. [DOI: 10.1016/j.arbr.2012.06.016] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
50 Raimondo G. Occult hepatitis B virus infection and liver disease: fact or fiction? Journal of Hepatology 2001;34:471-3. [DOI: 10.1016/s0168-8278(01)00016-2] [Cited by in Crossref: 26] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
51 MacConmara MP, Vachharajani N, Wellen JR, Anderson CD, Lowell JA, Shenoy S, Chapman WC, Doyle MB. Utilization of hepatitis B core antibody-positive donor liver grafts. HPB (Oxford). 2012;14:42-48. [PMID: 22151450 DOI: 10.1111/j.1477-2574.2011.00399.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 16] [Article Influence: 1.1] [Reference Citation Analysis]
52 Hatanaka K, Kudo M, Fukunaga T, Ueshima K, Chung H, Minami Y, Sakaguchi Y, Hagiwara S, Orino A, Osaki Y. Clinical characteristics of NonBNonC- HCC: Comparison with HBV and HCV related HCC. Intervirology. 2007;50:24-31. [PMID: 17164554 DOI: 10.1159/000096309] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 2.1] [Reference Citation Analysis]
53 López-Navidad A, Caballero F. Extended criteria for organ acceptance. Strategies for achieving organ safety and for increasing organ pool. Clin Transplant. 2003;17:308-324. [PMID: 12868987 DOI: 10.1034/j.1399-0012.2003.00119.x] [Cited by in Crossref: 103] [Cited by in F6Publishing: 74] [Article Influence: 5.4] [Reference Citation Analysis]
54 Park JS, Gayam V, Pan CQ. Review article: preventing hepatitis B graft infection in hepatitis B patients after liver transplantation: immunoglobulin vs anti-virals. Aliment Pharmacol Ther. 2020;52:944-954. [PMID: 32743822 DOI: 10.1111/apt.15999] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
55 Roche B, Roque-Afonso AM, Sebagh M, Delvart V, Duclos-Vallee JC, Castaing D, Samuel D. Escape hepatitis B virus mutations in recipients of antibody to hepatitis B core antigen-positive liver grafts receiving hepatitis B immunoglobulins. Liver Transpl. 2010;16:885-894. [PMID: 20583085 DOI: 10.1002/lt.22084] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 1.8] [Reference Citation Analysis]
56 Mahboobi N, Tabatabaei S, Blum H, Alavian S. Renal grafts from anti-hepatitis B core-positive donors: a quantitative review of the literature. Transpl Infect Dis 2012;14:445-51. [DOI: 10.1111/j.1399-3062.2012.00782.x] [Cited by in Crossref: 35] [Cited by in F6Publishing: 25] [Article Influence: 3.5] [Reference Citation Analysis]
57 Seem DL, Lee I, Umscheid CA, Kuehnert MJ; United States Public Health Service. PHS guideline for reducing human immunodeficiency virus, hepatitis B virus, and hepatitis C virus transmission through organ transplantation. Public Health Rep 2013;128:247-343. [PMID: 23814319 DOI: 10.1177/003335491312800403] [Cited by in Crossref: 158] [Cited by in F6Publishing: 127] [Article Influence: 17.6] [Reference Citation Analysis]
58 Kaplan DE, Reddy KR. Rising incidence of hepatocellular carcinoma: the role of hepatitis B and C; the impact on transplantation and outcomes. Clin Liver Dis 2003;7:683-714. [PMID: 14509534 DOI: 10.1016/s1089-3261(03)00060-6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
59 Hollinger FB. Hepatitis B virus infection and transfusion medicine: science and the occult. Transfusion. 2008;48:1001-1026. [PMID: 18454738 DOI: 10.1111/j.1537-2995.2008.01701.x] [Cited by in Crossref: 119] [Cited by in F6Publishing: 113] [Article Influence: 8.5] [Reference Citation Analysis]
60 Mutimer D. Positive suggestions about the anti-HBc positive donor. Gut 2002;50:7-8. [PMID: 11772957 DOI: 10.1136/gut.50.1.7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
61 Hui CK, Cheung WW, Zhang HY, Au WY, Yueng YH, Leung AY, Leung N, Luk JM, Lie AK, Kwong YL. Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy. Gastroenterology. 2006;131:59-68. [PMID: 16831590 DOI: 10.1053/j.gastro.2006.04.015] [Cited by in Crossref: 350] [Cited by in F6Publishing: 312] [Article Influence: 21.9] [Reference Citation Analysis]
62 Blanes M, Gomez D, Cordoba J, Almenar L, Gobernado M, Lopez-aldeguer J, Dicenta F. Is there any risk of transmission of hepatitis B from heart donors hepatitis B core antibody positive? Transplantation Proceedings 2002;34:61-2. [DOI: 10.1016/s0041-1345(01)02666-5] [Cited by in Crossref: 16] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
63 Lin CC, Chen CL, Concejero A, Wang CC, Wang SH, Liu YW, Yang CH, Yong CC, Lin TS, Jawan B. Active immunization to prevent de novo hepatitis B virus infection in pediatric live donor liver recipients. Am J Transplant. 2007;7:195-200. [PMID: 17227568 DOI: 10.1111/j.1600-6143.2006.01618.x] [Cited by in Crossref: 52] [Cited by in F6Publishing: 48] [Article Influence: 3.5] [Reference Citation Analysis]
64 Cheung CK, Lo CM, Man K, Lau GK. Occult hepatitis B virus infection of donor and recipient origin after liver transplantation despite nucleoside analogue prophylaxis. Liver Transpl. 2010;16:1314-1323. [PMID: 21031547 DOI: 10.1002/lt.22169] [Cited by in Crossref: 37] [Cited by in F6Publishing: 29] [Article Influence: 3.4] [Reference Citation Analysis]
65 Allain JP, Stramer SL, Carneiro-Proietti AB, Martins ML, Lopes da Silva SN, Ribeiro M, Proietti FA, Reesink HW. Transfusion-transmitted infectious diseases. Biologicals. 2009;37:71-77. [PMID: 19231236 DOI: 10.1016/j.biologicals.2009.01.002] [Cited by in Crossref: 96] [Cited by in F6Publishing: 80] [Article Influence: 7.4] [Reference Citation Analysis]
66 Wörns MA, Teufel A, Kanzler S, Shrestha A, Victor A, Otto G, Lohse AW, Galle PR, Höhler T. Incidence of HAV and HBV infections and vaccination rates in patients with autoimmune liver diseases. Am J Gastroenterol 2008;103:138-46. [PMID: 17970833 DOI: 10.1111/j.1572-0241.2007.01609.x] [Cited by in F6Publishing: 31] [Reference Citation Analysis]
67 Lake J. Hepatitis B immune globulin for life versus limited use: I favor limited duration of therapy. Liver Transplantation 2002;8:S90-1. [DOI: 10.1053/jlts.2002.35978] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
68 Hartwig MG, Patel V, Palmer SM, Cantu E, Appel JZ, Messier RH, Davis RD. Hepatitis B Core Antibody Positive Donors as a Safe and Effective Therapeutic Option to Increase Available Organs for Lung Transplantation: . Transplantation 2005;80:320-5. [DOI: 10.1097/01.tp.0000165858.86067.a2] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 1.7] [Reference Citation Analysis]
69 Hui C, Sun J, Au W, Lie AK, Yueng Y, Zhang H, Lee NP, Hou J, Liang R, Lau GK. Occult hepatitis B virus infection in hematopoietic stem cell donors in a hepatitis B virus endemic area. Journal of Hepatology 2005;42:813-9. [DOI: 10.1016/j.jhep.2005.01.018] [Cited by in Crossref: 69] [Cited by in F6Publishing: 63] [Article Influence: 4.1] [Reference Citation Analysis]
70 Allain J. Occult hepatitis B virus infection. Transfusion Clinique et Biologique 2004;11:18-25. [DOI: 10.1016/j.tracli.2003.11.007] [Cited by in Crossref: 92] [Cited by in F6Publishing: 91] [Article Influence: 5.1] [Reference Citation Analysis]
71 Deresinski SC. Hyperimmune products in the prevention and therapy of infectious disease: a report of a hyperimmune products expert advisory panel. BioDrugs 2000;14:147-58. [PMID: 18034567 DOI: 10.2165/00063030-200014030-00002] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
72 Rendon JC, Cortes-Mancera F, Restrepo-Gutierrez JC, Hoyos S, Navas MC. Molecular characterization of occult hepatitis B virus infection in patients with end-stage liver disease in Colombia. PLoS One 2017;12:e0180447. [PMID: 28686707 DOI: 10.1371/journal.pone.0180447] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
73 Angelis M, Cooper JT, Freeman RB. Impact of donor infections on outcome of orthotopic liver transplantation. Liver Transpl. 2003;9:451-462. [PMID: 12740786 DOI: 10.1053/jlts.2003.50094] [Cited by in Crossref: 71] [Cited by in F6Publishing: 54] [Article Influence: 3.7] [Reference Citation Analysis]
74 Pilmore HL, Gane EJ. Hepatitis B-positive donors in renal transplantation: increasing the deceased donor pool. Transplantation. 2012;94:205-210. [PMID: 22430067 DOI: 10.1097/tp.0b013e31824e3db4] [Cited by in Crossref: 29] [Cited by in F6Publishing: 5] [Article Influence: 2.9] [Reference Citation Analysis]
75 Allain J. Occult hepatitis B virus infection and transfusion. Journal of Hepatology 2006;44:617-8. [DOI: 10.1016/j.jhep.2005.12.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
76 Gao E, Hercun J, Heller T, Vilarinho S. Undiagnosed liver diseases. Transl Gastroenterol Hepatol 2021;6:28. [PMID: 33824932 DOI: 10.21037/tgh.2020.04.04] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
77 Joya-vazquez PP, Dodson FS, Dvorchik I, Gray E, Chesky A, Demetris AJ, Shakil O, Fung JJ, Vargas HE. Impact of anti-hepatitis Bc-positive grafts on the outcome of liver transplantation for HBV-related cirrhosis1: . Transplantation 2002;73:1598-602. [DOI: 10.1097/00007890-200205270-00013] [Cited by in Crossref: 47] [Cited by in F6Publishing: 36] [Article Influence: 2.4] [Reference Citation Analysis]
78 Nevens F, Zuckerman JN, Burroughs AK, Jung M, Bayas JM, Kallinowski B, Rivas EF, Duvoux C, Neuhaus P, Saliba F, Buti M, Zarski J, Pons F, Vanlemmens C, Hamtiaux V, Stoffel M. Immunogenicity and safety of an experimental adjuvanted hepatitis B candidate vaccine in liver transplant patients. Liver Transpl 2006;12:1489-95. [DOI: 10.1002/lt.20836] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 1.4] [Reference Citation Analysis]
79 Takemura N, Sugawara Y, Tamura S, Makuuchi M. Liver transplantation using hepatitis B core antibody-positive grafts: review and university of Tokyo experience. Dig Dis Sci. 2007;52:2472-2477. [PMID: 17805972 DOI: 10.1007/s10620-006-9656-5] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 1.7] [Reference Citation Analysis]
80 Yu AS, Vierling JM, Colquhoun SD, Arnaout WS, Chan CK, Khanafshar E, Geller SA, Nichols WS, Fong TL. Transmission of hepatitis B infection from hepatitis B core antibody--positive liver allografts is prevented by lamivudine therapy. Liver Transpl. 2001;7:513-517. [PMID: 11443579 DOI: 10.1053/jlts.2001.23911] [Cited by in Crossref: 83] [Cited by in F6Publishing: 71] [Article Influence: 4.0] [Reference Citation Analysis]
81 Roche B, Samuel D. Evolving strategies to prevent HBV recurrence. Liver Transpl 2004;10:S74-85. [DOI: 10.1002/lt.20258] [Cited by in Crossref: 63] [Cited by in F6Publishing: 52] [Article Influence: 3.5] [Reference Citation Analysis]
82 Lee KH, Wai CT, Lim SG, Manjit K, Lee HL, Da Costa M, Quak SH, Tan KC. Risk for de novo hepatitis B from antibody to hepatitis B core antigen-positive donors in liver transplantation in Singapore. Liver Transpl. 2001;7:469-470. [PMID: 11349271 DOI: 10.1002/lt.500070514] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 0.9] [Reference Citation Analysis]
83 Kim HY, Choi JY, Park CH, Song MJ, Jang JW, Chang UI, Bae SH, Yoon SK, Han JY, Kim DG. Adult Living Donor Liver Transplantation Using Hepatitis B Core Antibody-Positive Grafts in Korea, a Hepatitis B-endemic Region. Gut Liver. 2011;5:363-366. [PMID: 21927667 DOI: 10.5009/gnl.2011.5.3.363] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
84 Roche B, Samuel D. [Prevention and treatment of hepatitis B virus infection after liver transplantation]. Gastroenterol Clin Biol 2005;29:393-404. [PMID: 15864201 DOI: 10.1016/s0399-8320(05)80787-0] [Reference Citation Analysis]
85 Minuk GY, Sun DF, Greenberg R, Zhang M, Hawkins K, Uhanova J, Gutkin A, Bernstein K, Giulivi A, Osiowy C. Occult hepatitis B virus infection in a North American adult hemodialysis patient population. Hepatology. 2004;40:1072-1077. [PMID: 15486926 DOI: 10.1002/hep.20435] [Cited by in Crossref: 94] [Cited by in F6Publishing: 87] [Article Influence: 5.2] [Reference Citation Analysis]
86 Hui C, Cheung WW, Chan S, Lo C, Lau GK. Hepatitis B vaccination and preemptive treatment of hepatitis B virus in liver transplantation. Current Opinion in Organ Transplantation 2006;11:594-8. [DOI: 10.1097/mot.0b013e32801040bf] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
87 Maek-A-Nantawat W, Avihingsanon A, Ohata PJ. Challenges in Providing Treatment and Care for Viral Hepatitis among Individuals Co-Infected with HIV in Resource-Limited Settings. AIDS Res Treat 2012;2012:948059. [PMID: 22536498 DOI: 10.1155/2012/948059] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
88 Stark K, Günther M, Schönfeld C, Tullius SG, Bienzle U. Immunisations in solid-organ transplant recipients. Lancet 2002;359:957-65. [PMID: 11918932 DOI: 10.1016/S0140-6736(02)08028-5] [Cited by in Crossref: 56] [Cited by in F6Publishing: 5] [Article Influence: 2.8] [Reference Citation Analysis]
89 Chanpong A, Angkathunyakul N, Sornmayura P, Tanpowpong P, Lertudomphonwanit C, Panpikoon T, Treepongkaruna S. Late allograft fibrosis in pediatric liver transplant recipients: Assessed by histology and transient elastography. Pediatr Transplant 2019;23:e13541. [PMID: 31278842 DOI: 10.1111/petr.13541] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
90 Osborn M, Guest J, Rimland D. Hepatitis B virus and HIV coinfection: relationship of different serological patterns to survival and liver disease. HIV Med 2007;8:271-9. [DOI: 10.1111/j.1468-1293.2007.00469.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 1.5] [Reference Citation Analysis]
91 Roche B, Samuel D. Treatment of hepatitis B and C after liver transplantation. Part 1, hepatitis B. Transpl Int 2005;17:746-58. [PMID: 15688165 DOI: 10.1007/s00147-004-0797-1] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
92 Grossi P, Dalla Gasperina D, Furione M, Viganò M, Minoli L. Lamivudine treatment for HBV infection following thoracic organ transplantation. Transplantation Proceedings 2001;33:1576-8. [DOI: 10.1016/s0041-1345(00)02599-9] [Cited by in Crossref: 6] [Article Influence: 0.3] [Reference Citation Analysis]
93 Perrillo R. Hepatitis B virus prevention strategies for antibody to hepatitis B core antigen-positive liver donation: a survey of North American, European, and Asian-Pacific transplant programs. Liver Transpl. 2009;15:223-232. [PMID: 19177436 DOI: 10.1002/lt.21675] [Cited by in Crossref: 58] [Cited by in F6Publishing: 50] [Article Influence: 4.5] [Reference Citation Analysis]
94 Allain JP. Epidemiology of Hepatitis B virus and genotype. J Clin Virol. 2006;36 Suppl 1:S12-S17. [PMID: 16831687 DOI: 10.1016/s1386-6532(06)80003-x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
95 Van Thiel DH, De Maria N, Colantoni A, Friedlander L. Can hepatitis B core antibody positive livers be used safely for transplantation: hepatitis B virus detection in the liver of individuals who are hepatitis B core antibody positive. Transplantation 1999;68:519-22. [PMID: 10480410 DOI: 10.1097/00007890-199908270-00013] [Cited by in Crossref: 39] [Cited by in F6Publishing: 34] [Article Influence: 1.7] [Reference Citation Analysis]
96 Aggeletopoulou I, Konstantakis C, Manolakopoulos S, Triantos C. Risk of hepatitis B reactivation in patients treated with direct-acting antivirals for hepatitis C. World J Gastroenterol 2017; 23(24): 4317-4323 [PMID: 28706414 DOI: 10.3748/wjg.v23.i24.4317] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
97 Bonatti H, Sawyer R, Dickson RC, Razonable R, Schmitt T, Mendez J, Singh N, Pruett T. Transmission of viral disease to the recipient through the donor liver: . Current Opinion in Organ Transplantation 2007;12:231-41. [DOI: 10.1097/mot.0b013e32814e6b67] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
98 de Villa VH, Chen YS, Chen CL. Hepatitis B core antibody-positive grafts: recipient's risk. Transplantation. 2003;75:S49-S53. [PMID: 12589141 DOI: 10.1097/01.tp.0000047006.96782.64] [Cited by in Crossref: 51] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
99 Allain JP. Occult hepatitis B virus infection: implications in transfusion. Vox Sang. 2004;86:83-91. [PMID: 15023176 DOI: 10.1111/j.0042-9007.2004.00406.x] [Cited by in Crossref: 192] [Cited by in F6Publishing: 187] [Article Influence: 10.7] [Reference Citation Analysis]
100 Lo CM, Fan ST, Liu CL, Yong BH, Wong Y, Ng IO, Wong J. Safety and outcome of hepatitis B core antibody-positive donors in right-lobe living donor liver transplantation. Liver Transpl. 2003;9:827-832. [PMID: 12884195 DOI: 10.1053/jlts.2003.50115] [Cited by in Crossref: 33] [Cited by in F6Publishing: 27] [Article Influence: 1.7] [Reference Citation Analysis]
101 Raimondo G, Pollicino T, Cacciola I, Squadrito G. Occult hepatitis B virus infection. J Hepatol. 2007;46:160-170. [PMID: 17112622 DOI: 10.1016/j.jhep.2006.10.007] [Cited by in Crossref: 335] [Cited by in F6Publishing: 326] [Article Influence: 20.9] [Reference Citation Analysis]
102 Viral hepatitis guidelines in hemodialysis and transplantation Am J Transplant. 2004;4 Suppl 10:72-82. [PMID: 15504218 DOI: 10.1111/j.1600-6135.2004.00676.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.4] [Reference Citation Analysis]
103 Wu KT, Chung KM, Feng IC, Sheu MJ, Kuo HT, Koay LB, Lin CY, Tang LY, Tsai SL. Acute hepatitis E virus infection in Taiwan 2002-2006 revisited: PCR shows frequent co-infection with multiple hepatitis viruses. J Med Virol 2009;81:1734-42. [PMID: 19697413 DOI: 10.1002/jmv.21442] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
104 Domen RE, Yen-Lieberman B, Nelson KA, Chua J, Sholtis W, Tyus H, Isada CM. Use of an HBV-DNA hybridization assay in the evaluation of equivocal hepatitis B virus tests in solid organ donors. Prog Transplant 2000;10:42-6. [PMID: 10941326 DOI: 10.7182/prtr.10.1.31037k70l5057170] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.0] [Reference Citation Analysis]
105 Wiesner RH, Menon KV. Late hepatic allograft dysfunction. Liver Transpl. 2001;7:S60-S73. [PMID: 11689778 DOI: 10.1053/jlts.2001.29094] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 1.4] [Reference Citation Analysis]
106 Khorami F, Sobhani SA, Davoudian P, Khajeh E. Prevalence of HBc-Ab among HBs-Ag negative healthy blood donors in south of Iran. Electron Physician 2013;5:659-63. [PMID: 26120400 DOI: 10.14661/2013.659-663] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
107 Yano Y, Yamashita F, Sumie S, Ando E, Fukumori K, Kiyama M, Oyama T, Kuroki S, Kato O, Yamamoto H. Clinical features of hepatocellular carcinoma seronegative for both HBsAg and anti-HCV antibody but positive for anti-HBc antibody in Japan. Am J Gastroenterol. 2002;97:156-161. [PMID: 11808941 DOI: 10.1111/j.1572-0241.2002.05440.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 0.9] [Reference Citation Analysis]
108 Lok AS. Occult hepatitis B virus infection: diagnosis, implications and management? J Gastroenterol Hepatol 2004;19:S114-7. [DOI: 10.1111/j.1440-1746.2004.03657.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
109 Kornberg A. Intravenous immunoglobulins in liver transplant patients: Perspectives of clinical immune modulation. World J Hepatol 2015; 7(11): 1494-1508 [PMID: 26085909 DOI: 10.4254/wjh.v7.i11.1494] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
110 Dodson SF, Bonham CA, Geller DA, Cacciarelli TV, Rakela J, Fung JJ. PREVENTION OF DE NOVO HEPATITIS B INFECTION IN RECIPIENTS OF HEPATIC ALLOGRAFTS FROM ANTI-HBc POSITIVE DONORS: . Transplantation 1999;68:1058-61. [DOI: 10.1097/00007890-199910150-00028] [Cited by in Crossref: 121] [Cited by in F6Publishing: 106] [Article Influence: 5.3] [Reference Citation Analysis]
111 Crismale JF, Ahmad J. Expanding the donor pool: Hepatitis C, hepatitis B and human immunodeficiency virus-positive donors in liver transplantation. World J Gastroenterol 2019; 25(47): 6799-6812 [PMID: 31885421 DOI: 10.3748/wjg.v25.i47.6799] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
112 Madhavan A, Sachu A, Balakrishnan AK, Balakrishnan S, Vasudevapanicker J. Prevalence of Anti-HBc Antibodies among HBsAg Negative Individuals and Its Association with Occult Hepatitis B. J Lab Physicians 2021;13:1-5. [PMID: 34054234 DOI: 10.1055/s-0041-1723046] [Reference Citation Analysis]
113 Lee YJ, Oh SH, Kim KM, Song SM, Namgoong JM, Kim DY, Lee SG. De novo hepatitis B virus infection after pediatric liver transplantations with hepatitis B core antibody-positive donors: a single-center 20-yr experience. Pediatr Transplant. 2015;19:267-272. [PMID: 25648049 DOI: 10.1111/petr.12432] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
114 Yataco ML, Dickson RC, Bonatti H, Aranda-michel J, Mendez J, Ghabril M, Nguyen J. Dual hepatitis virus infections in liver transplant: case report and a review of the literature. Clinical Transplantation 2009;23:282-8. [DOI: 10.1111/j.1399-0012.2008.00929.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
115 Cholongitas E, Papatheodoridis GV, Burroughs AK. Liver grafts from anti-hepatitis B core positive donors: a systematic review. J Hepatol. 2010;52:272-279. [PMID: 20034693 DOI: 10.1016/j.jhep.2009.11.009] [Cited by in Crossref: 185] [Cited by in F6Publishing: 146] [Article Influence: 15.4] [Reference Citation Analysis]
116 Dumortier J, Chevallier P, Scoazec J, Boillot O. HBV reactivation in the recipient of a liver graft from an anti-HBc positive donor despite post-vaccination antibodies to hepatitis B surface antigen. Journal of Hepatology 2002;37:876-7. [DOI: 10.1016/s0168-8278(02)00320-3] [Cited by in Crossref: 5] [Article Influence: 0.3] [Reference Citation Analysis]
117 Gallegos-orozco JF, Vargas HE, Rakela J. Virologically compromised donor grafts in liver transplantation. Journal of Hepatology 2004;41:512-21. [DOI: 10.1016/j.jhep.2004.08.003] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
118 Zeiler T, Karger R, Slonka J, Radsak K, Kretschmer V. Introducing Anti-HBc Screening in Germany – Possible Implications for the Blood Donation Service. Transfus Med Hemother 2006;33:453-8. [DOI: 10.1159/000094784] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
119 Yu AS, Keeffe EB. Nucleoside analogues and other antivirals for treatment of hepatitis B in the peritransplant period. Clinics in Liver Disease 2003;7:551-72. [DOI: 10.1016/s1089-3261(03)00044-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
120 Nery JR, Nery-Avila C, Reddy KR, Cirocco R, Weppler D, Levi DM, Nishida S, Madariaga J, Kato T, Ruiz P. Use of liver grafts from donors positive for antihepatitis B-core antibody (anti-HBc) in the era of prophylaxis with hepatitis-B immunoglobulin and lamivudine. Transplantation. 2003;75:1179-1186. [PMID: 12717200 DOI: 10.1097/01.tp.0000065283.98275.fe] [Cited by in Crossref: 69] [Cited by in F6Publishing: 16] [Article Influence: 3.6] [Reference Citation Analysis]
121 Chang SH, Suh KS, Yi NJ, Choi SH, Lee HJ, Seo JK, Lee KU. Active immunization against de novo hepatitis B virus infection in pediatric patients after liver transplantation. Hepatology. 2003;37:1329-1334. [PMID: 12774011 DOI: 10.1053/jhep.2003.50227] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 1.8] [Reference Citation Analysis]
122 Anwar N, Sherman KE. Transplanting organs from hepatitis B positive donors: Is it safe? Is it ethical? J Viral Hepat. 2018;25:1110-1115. [PMID: 29968277 DOI: 10.1111/jvh.12962] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
123 Dhillon GS, Levitt J, Mallidi H, Valentine VG, Gupta MR, Sista R, Weill D. Impact of Hepatitis B Core Antibody Positive Donors in Lung and Heart-Lung Transplantation: An Analysis of the United Network for Organ Sharing Database. Transplantation 2009;88:842-6. [DOI: 10.1097/tp.0b013e3181b4e1fd] [Cited by in Crossref: 28] [Cited by in F6Publishing: 5] [Article Influence: 2.2] [Reference Citation Analysis]
124 Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology. 2007;45:507-539. [PMID: 17256718 DOI: 10.1002/hep.21513] [Cited by in Crossref: 1675] [Cited by in F6Publishing: 1543] [Article Influence: 111.7] [Reference Citation Analysis]
125 Samuel D, Roque-afonso AM. New sensitive tools for hepatitis B virus (HBV) detection in liver transplantation: What will be their impact on the prophylaxis of HBV infection? Liver Transpl 2007;13:1084-7. [DOI: 10.1002/lt.21156] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
126 Flores PA, Vierling JM. Modifications of immunosuppression in hepatitis B virus infection: . Current Opinion in Organ Transplantation 2001;6:331-7. [DOI: 10.1097/00075200-200112000-00011] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
127 Rodriguez-luna H, Arenas J, Vargas HE. The use of virologically compromised organs in liver transplantation. Clinics in Liver Disease 2003;7:573-84. [DOI: 10.1016/s1089-3261(03)00056-4] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
128 Pereira AA, Jacobson IM. Modern diagnosis of HBV infection. Curr hepatitis rep 2009;8:18-25. [DOI: 10.1007/s11901-009-0003-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
129 Avolio AW, Cillo U, Salizzoni M, De Carlis L, Colledan M, Gerunda GE, Mazzaferro V, Tisone G, Romagnoli R, Caccamo L, Rossi M, Vitale A, Cucchetti A, Lupo L, Gruttadauria S, Nicolotti N, Burra P, Gasbarrini A, Agnes S; On behalf of the Donor‐to‐Recipient Italian Liver Transplant (D2R‐ILTx) Study Group. Balancing Donor and Recipient Risk Factors in Liver Transplantation: The Value of D‐MELD With Particular Reference to HCV Recipients. American Journal of Transplantation 2011;11:2724-36. [DOI: 10.1111/j.1600-6143.2011.03732.x] [Cited by in Crossref: 73] [Cited by in F6Publishing: 68] [Article Influence: 6.6] [Reference Citation Analysis]
130 White SL, Rawlinson W, Boan P, Sheppeard V, Wong G, Waller K, Opdam H, Kaldor J, Fink M, Verran D, Webster A, Wyburn K, Grayson L, Glanville A, Cross N, Irish A, Coates T, Griffin A, Snell G, Alexander SI, Campbell S, Chadban S, Macdonald P, Manley P, Mehakovic E, Ramachandran V, Mitchell A, Ison M. Infectious Disease Transmission in Solid Organ Transplantation: Donor Evaluation, Recipient Risk, and Outcomes of Transmission. Transplant Direct 2019;5:e416. [PMID: 30656214 DOI: 10.1097/TXD.0000000000000852] [Cited by in Crossref: 19] [Cited by in F6Publishing: 9] [Article Influence: 4.8] [Reference Citation Analysis]
131 Loss GE, Mason AL, Nair S, Blazek J, Farr G, Guo L, Cohen AJ, Eason JD. Does lamivudine prophylaxis eradicate persistent HBV DNA from allografts derived from anti-HBc-positive donors? Liver Transpl. 2003;9:1258-1264. [PMID: 14625825 DOI: 10.1016/j.lts.2003.09.010] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 1.4] [Reference Citation Analysis]
132 Savas N, Colak T, Yilmaz U, Emiroglu R, Haberal M. Hepatitis B virus reactivation after renal transplantation: report of two cases. Transplant Int 2007;20:301-4. [DOI: 10.1111/j.1432-2277.2006.00427.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
133 Riveiro-Barciela M. Outcome and risk of de novo Hepatitis B after liver transplantation: Are all anti-HBc-positive grafts the same? Clin Res Hepatol Gastroenterol 2020;44:791-3. [PMID: 32586783 DOI: 10.1016/j.clinre.2020.05.016] [Reference Citation Analysis]
134 Campe H, Hillebrand GF, Mairhofer H, Nitschko H, Jäger G. Undetected chronic hepatitis B virus infection of a vaccinated dialysis patient after liver transplantation. Nephrol Dial Transplant 2005;20:1492-4. [PMID: 15840679 DOI: 10.1093/ndt/gfh823] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
135 Delmonico FL. Cadaver donor screening for infectious agents in solid organ transplantation. Clin Infect Dis. 2000;31:781-786. [PMID: 11017830 DOI: 10.1086/314000] [Cited by in Crossref: 61] [Cited by in F6Publishing: 43] [Article Influence: 2.8] [Reference Citation Analysis]
136 Eisenbach C, Sauer P, Mehrabi A, Stremmel W, Encke J. Prevention of hepatitis B virus recurrence after liver transplantation. Clin Transplant 2006;20 Suppl 17:111-6. [PMID: 17100710 DOI: 10.1111/j.1399-0012.2006.00609.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
137 Saijo T, Joki N, Inishi Y, Muto M, Saijo M, Hase H. Occult hepatitis B virus infection in hemodialysis patients in Japan. Ther Apher Dial 2015;19:125-30. [PMID: 25363685 DOI: 10.1111/1744-9987.12241] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
138 Horlander JC, Boyle N, Manam R, Schenk M, Herring S, Kwo PY, Lumeng L, Chalasani N. Vaccination against Hepatitis B in Patients with Chronic Liver Disease Awaiting Liver Transplantation. The American Journal of the Medical Sciences 1999;318:304-7. [DOI: 10.1016/s0002-9629(15)40643-3] [Cited by in Crossref: 33] [Article Influence: 1.4] [Reference Citation Analysis]
139 Wedemeyer H, Pethig K, Wagner D, Flemming P, Oppelt P, Petzold DR, Haverich A, Manns MP, Boeker KH. LONG-TERM OUTCOME OF CHRONIC HEPATITIS B IN HEART TRANSPLANT RECIPIENTS: . Transplantation 1998;66:1347-53. [DOI: 10.1097/00007890-199811270-00015] [Cited by in Crossref: 53] [Cited by in F6Publishing: 51] [Article Influence: 2.2] [Reference Citation Analysis]
140 Arslan M, Wiesner RH, Sievers C, Egan K, Zein NN. Double-dose accelerated hepatitis B vaccine in patients with end-stage liver disease. Liver Transpl 2001;7:314-20. [DOI: 10.1053/jlts.2001.23069] [Cited by in Crossref: 67] [Cited by in F6Publishing: 57] [Article Influence: 3.2] [Reference Citation Analysis]
141 Gane E, Pilmore H. Management of chronic viral hepatitis before and after renal transplantation. Transplantation. 2002;74:427-437. [PMID: 12352899 DOI: 10.1097/00007890-200208270-00001] [Cited by in Crossref: 123] [Cited by in F6Publishing: 92] [Article Influence: 6.2] [Reference Citation Analysis]
142 Mattner F, Kola A, Fischer S, Becker T, Haverich A, Simon A, Suerbaum S, Gastmeier P, Weißbrodt H, Strüber M. Impact of Bacterial and Fungal Donor Organ Contamination in Lung, Heart–Lung, Heart and Liver Transplantation. Infection 2008;36:207-12. [DOI: 10.1007/s15010-007-7157-x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 20] [Article Influence: 2.2] [Reference Citation Analysis]
143 Rubin RH. Infection in the Organ Transplant Recipient. In: Rubin RH, Young LS, Van Furth R, editors. Clinical Approach to Infection in the Compromised Host. Boston: Springer US; 2002. pp. 573-679. [DOI: 10.1007/0-306-47527-8_17] [Cited by in Crossref: 30] [Cited by in F6Publishing: 21] [Article Influence: 1.5] [Reference Citation Analysis]
144 Koziel MJ, Thio CL. Hepatitis B Virus and Hepatitis Delta Virus. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. Elsevier; 2010. pp. 2059-86. [DOI: 10.1016/b978-0-443-06839-3.00146-6] [Cited by in Crossref: 5] [Article Influence: 0.4] [Reference Citation Analysis]
145 Keeffe EB. Liver transplantation: current status and novel approaches to liver replacement. Gastroenterology. 2001;120:749-762. [PMID: 11179248 DOI: 10.1053/gast.2001.22583] [Cited by in Crossref: 166] [Cited by in F6Publishing: 142] [Article Influence: 7.9] [Reference Citation Analysis]
146 Raimondo G, Pollicino T, Romanò L, Zanetti AR. A 2010 update on occult hepatitis B infection. Pathol Biol (Paris). 2010;58:254-257. [PMID: 20303674 DOI: 10.1016/j.patbio.2010.02.003] [Cited by in Crossref: 76] [Cited by in F6Publishing: 81] [Article Influence: 6.3] [Reference Citation Analysis]
147 Sawyer LA. Antibodies for the prevention and treatment of viral diseases. Antiviral Res 2000;47:57-77. [PMID: 10996394 DOI: 10.1016/s0166-3542(00)00111-x] [Cited by in Crossref: 93] [Cited by in F6Publishing: 43] [Article Influence: 4.2] [Reference Citation Analysis]
148 Chen H, Su T, Tseng T, Yang W, Chen T, Chen P, Chen D, Kao J, Liu C. Impact of occult hepatitis B on the clinical outcomes of patients with chronic hepatitis C virus infection: A 10-year follow-up. Journal of the Formosan Medical Association 2017;116:697-704. [DOI: 10.1016/j.jfma.2016.11.002] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
149 Günther S. Genetic variation in HBV infection: genotypes and mutants. J Clin Virol 2006;36 Suppl 1:S3-S11. [PMID: 16831690 DOI: 10.1016/s1386-6532(06)80002-8] [Cited by in Crossref: 27] [Cited by in F6Publishing: 18] [Article Influence: 1.7] [Reference Citation Analysis]
150 Hara Y, Tokodai K, Nakanishi C, Miyagi S, Kawagishi N. Spontaneous resolution of de novo hepatitis B after living donor liver transplantation with hepatitis B core antibody positive graft: a case report. Surg Case Rep. 2016;2:118. [PMID: 27797067 DOI: 10.1186/s40792-016-0246-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
151 Gibney KB, Torresi J, Lemoh C, Biggs BA. Isolated core antibody hepatitis B in sub-Saharan African immigrants. J Med Virol 2008;80:1565-9. [PMID: 18649341 DOI: 10.1002/jmv.21267] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 1.6] [Reference Citation Analysis]
152 Fong T, Bunnapradist S, Jordan SC, Cho YW. IMPACT OF HEPATITIS B CORE ANTIBODY STATUS ON OUTCOMES OF CADAVERIC RENAL TRANSPLANTATION: ANALYSIS OF UNITED NETWORK OF ORGAN SHARING DATABASE BETWEEN 1994 AND 1999. Transplantation 2002;73:85-9. [DOI: 10.1097/00007890-200201150-00016] [Cited by in Crossref: 46] [Cited by in F6Publishing: 31] [Article Influence: 2.3] [Reference Citation Analysis]
153 Verna EC. Updated Hepatitis B Guidance: Implications for liver transplant patients. Liver Transpl 2018;24:465-9. [PMID: 29466838 DOI: 10.1002/lt.25037] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
154 Hass M, Hannoun C, Kalinina T, Sommer G, Manegold C, Günther S. Functional analysis of hepatitis B virus reactivating in hepatitis B surface antigen-negative individuals. Hepatology. 2005;42:93-103. [PMID: 15962285 DOI: 10.1002/hep.20748] [Cited by in Crossref: 64] [Cited by in F6Publishing: 71] [Article Influence: 3.8] [Reference Citation Analysis]
155 Abd Muain MF, Cheo KH, Omar MN, Amir Hamzah AS, Lim HN, Salleh AB, Tan WS, Ahmad Tajudin A. Gold nanoparticle-decorated reduced-graphene oxide targeting anti hepatitis B virus core antigen. Bioelectrochemistry 2018;122:199-205. [PMID: 29660648 DOI: 10.1016/j.bioelechem.2018.04.004] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
156 Routh D, Naidu S, Sharma S, Ranjan P, Godara R. Changing pattern of donor selection criteria in deceased donor liver transplant: a review of literature. J Clin Exp Hepatol. 2013;3:337-346. [PMID: 25755521 DOI: 10.1016/j.jceh.2013.11.007] [Cited by in Crossref: 30] [Cited by in F6Publishing: 23] [Article Influence: 3.3] [Reference Citation Analysis]
157 Loss GE, Mason AL, Blazek J, Dick D, Lipscomb J, Guo L, Perrillo RP, Eason JD. Transplantation of livers from hbc Ab positive donors into HBc Ab negative recipients: a strategy and preliminary results. Clin Transplant. 2001;15 Suppl 6:55-58. [PMID: 11903388 DOI: 10.1034/j.1399-0012.2001.00010.x] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 1.5] [Reference Citation Analysis]
158 Hoofnagle JH. Reactivation of hepatitis B. Hepatology. 2009;49:S156-S165. [PMID: 19399803 DOI: 10.1002/hep.22945] [Cited by in Crossref: 375] [Cited by in F6Publishing: 327] [Article Influence: 28.8] [Reference Citation Analysis]
159 Regev A, Schiff ER. Viral hepatitis A, B, and C. Clin Liver Dis 2000;4:47-71, vi. [PMID: 11232191 DOI: 10.1016/s1089-3261(05)70096-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
160 Marusawa H, Osaki Y, Kimura T, Ito K, Yamashita Y, Eguchi T, Kudo M, Yamamoto Y, Kojima H, Seno H, Moriyasu F, Chiba T. High prevalence of anti-hepatitis B virus serological markers in patients with hepatitis C virus related chronic liver disease in Japan. Gut 1999;45:284-8. [PMID: 10403743 DOI: 10.1136/gut.45.2.284] [Cited by in Crossref: 53] [Cited by in F6Publishing: 53] [Article Influence: 2.3] [Reference Citation Analysis]
161 Ye X, Li T, Xu X, Du P, Zeng J, Zhu W, Yang B, Li C, Allain JP. Characterisation and follow-up study of occult hepatitis B virus infection in anti-HBc-positive qualified blood donors in southern China. Blood Transfus 2017;15:6-12. [PMID: 27416568 DOI: 10.2450/2016.0268-15] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
162 Berenguer M, Wright TL. Treatment of recurrence of hepatitis B in transplant patients. Journal of Hepatology 2003;39:190-3. [DOI: 10.1016/s0168-8278(03)00350-7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
163 Mueller NJ, Fishman JA. How should we evaluate organ donors with active or prior infections? Journal of Hepatology 2006;45:507-13. [DOI: 10.1016/j.jhep.2006.07.020] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
164 Pruett TL. Editorial response: De novo HBV infections after liver transplantation. Liver Transpl 1998;4:182-4. [DOI: 10.1002/lt.500040209] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
165 Yotsuyanagi H, Yasuda K, Moriya K, Shintani Y, Fujie H, Tsutsumi T, Nojiri N, Juji T, Hoshino H, Shimoda K, Hino K, Kimura S, Iino S, Koike K. Frequent presence of HBV in the sera of HBsAg-negative, anti-HBc-positive blood donors. Transfusion. 2001;41:1093-1099. [PMID: 11552064 DOI: 10.1046/j.1537-2995.2001.41091093.x] [Cited by in Crossref: 61] [Cited by in F6Publishing: 65] [Article Influence: 2.9] [Reference Citation Analysis]
166 Barcena R, Moraleda G, Moreno J, Martín MD, Vicente E, Nuño J, Mateos ML, Campo SD. Prevention of de novo HBV infection by the presence of anti-HBs in transplanted patients receiving core antibody-positive livers. World J Gastroenterol 2006; 12(13): 2070-2074 [PMID: 16610059 DOI: 10.3748/wjg.v12.i13.2070] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 22] [Article Influence: 1.4] [Reference Citation Analysis]
167 Marusawa H, Uemoto S, Hijikata M, Ueda Y, Tanaka K, Shimotohno K, Chiba T. Latent hepatitis B virus infection in healthy individuals with antibodies to hepatitis B core antigen. Hepatology. 2000;31:488-495. [PMID: 10655275 DOI: 10.1002/hep.510310232] [Cited by in Crossref: 162] [Cited by in F6Publishing: 165] [Article Influence: 7.4] [Reference Citation Analysis]
168 Perrillo RP. Therapy of hepatitis B — Viral suppression or eradication? Hepatology 2006;43:S182-93. [DOI: 10.1002/hep.20970] [Cited by in Crossref: 45] [Cited by in F6Publishing: 35] [Article Influence: 2.8] [Reference Citation Analysis]
169 Jones JM, Kracalik I, Levi ME, Bowman JS 3rd, Berger JJ, Bixler D, Buchacz K, Moorman A, Brooks JT, Basavaraju SV. Assessing Solid Organ Donors and Monitoring Transplant Recipients for Human Immunodeficiency Virus, Hepatitis B Virus, and Hepatitis C Virus Infection - U.S. Public Health Service Guideline, 2020. MMWR Recomm Rep 2020;69:1-16. [PMID: 32584804 DOI: 10.15585/mmwr.rr6904a1] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 8.0] [Reference Citation Analysis]
170 Perrillo R, Nair S. Hepatitis B. Zakim and Boyer's Hepatology. Elsevier; 2006. pp. 635-63. [DOI: 10.1016/b978-1-4160-3258-8.50036-x] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
171 Castells L, Vargas V, Rodr[iacute]guez F, Allende H, Buti M, S[aacute]nchez-avila JF, Jard[iacute] R, Margarit C, Pumarola T, Esteban R, Guardia J. Clinical impact and efficacy of lamivudine therapy in de novo hepatitis B infection after liver transplantation. Liver Transplantation;8:892-900. [DOI: 10.1053/jlts.2002.35555] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 1.2] [Reference Citation Analysis]
172 Castells L, Vargas V, Rodrı́guez-frı́as F, Allende H, Jardı́ R, Margarit C, Esteban R, Guardia J. Transmission of hepatitis B virus by transplantation of livers from donors positive for antibody to hepatitis B core antigen. Transplantation Proceedings 1999;31:2464-5. [DOI: 10.1016/s0041-1345(99)00419-4] [Cited by in Crossref: 26] [Cited by in F6Publishing: 2] [Article Influence: 1.1] [Reference Citation Analysis]
173 Tanaka E, Umemura T. History and prevention of de novo hepatitis B virus-related hepatitis in Japan and the world. Clin J Gastroenterol 2008;1:83-6. [DOI: 10.1007/s12328-008-0030-3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
174 Tanaka H, Iwasaki Y, Nouso K, Kobayashi Y, Nakamura S, Matsumoto E, Toshikuni N, Kaneyoshi T, Ohsawa T, Takaguchi K, Fujio K, Senoh T, Ohnishi T, Sakaguchi K, Shiratori Y. Possible contribution of prior hepatitis B virus infection to the development of hepatocellular carcinoma. J Gastroenterol Hepatol 2005;20:850-6. [PMID: 15946131 DOI: 10.1111/j.1440-1746.2005.03823.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.4] [Reference Citation Analysis]
175 N/A. N/A. Shijie Huaren Xiaohua Zazhi 2003; 11(2): 246-248 [DOI: 10.11569/wcjd.v11.i2.246] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
176 Manickam P, Krishnamoorthi R, Kanaan Z, Gunasekaran P, Cappell M. Prognostic implications of recipient or donor hepatitis B seropositivity in thoracic transplantation: analysis of 426 hepatitis B surface antigen-positive recipients. Transpl Infect Dis 2014;16:597-604. [DOI: 10.1111/tid.12256] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
177 Loggi E, Bihl F, Chisholm JV, Biselli M, Bontadini A, Vitale G, Ercolani G, Grazi GL, Pinna AD, Bernardi M. Anti-HBs re-seroconversion after liver transplantation in a patient with past HBV infection receiving a HBsAg positive graft. J Hepatol. 2009;50:625-630. [PMID: 19157623 DOI: 10.1016/j.jhep.2008.08.026] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 2.4] [Reference Citation Analysis]
178 Vargas HE, Dodson FS, Rakela J. A concise update on the status of liver transplantation for hepatitis B virus: the challenges in 2002. Liver Transpl. 2002;8:2-9. [PMID: 11799479 DOI: 10.1053/jlts.2002.29765] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 1.3] [Reference Citation Analysis]
179 Su WJ, Ho MC, Ni YH, Chen HL, Hu RH, Wu YM, Chang MH, Lee PH. High-titer antibody to hepatitis B surface antigen before liver transplantation can prevent de novo hepatitis B infection. J Pediatr Gastroenterol Nutr. 2009;48:203-208. [PMID: 19179883 DOI: 10.1097/mpg.0b013e3181819ad4] [Cited by in Crossref: 37] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
180 Swierkosz EM. Nosocomial viral infections revisited. Clinical Microbiology Newsletter 2001;23:43-8. [DOI: 10.1016/s0196-4399(01)88006-5] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
181 Soejima Y, Ikegami T, Taketomi A, Yoshizumi T, Uchiyama H, Harada N, Yamashita Y, Maehara Y. Hepatitis B vaccination after living donor liver transplantation. Liver Int 2007;27:977-82. [DOI: 10.1111/j.1478-3231.2007.01521.x] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 2.0] [Reference Citation Analysis]
182 Fabrizi F, Messa PG, Lunghi G, Aucella F, Bisegna S, Mangano S, Villa M, Barbisoni F, Rusconi E, Martin P. Occult hepatitis B virus infection in dialysis patients: a multicentre survey. Aliment Pharmacol Ther 2005;21:1341-7. [PMID: 15932364 DOI: 10.1111/j.1365-2036.2005.02501.x] [Cited by in Crossref: 44] [Cited by in F6Publishing: 46] [Article Influence: 2.6] [Reference Citation Analysis]
183 Fabris P, Brown D, Tositti G, Bozzola L, Giordani MT, Bevilacqua P, de Lalla F, Webster GJ, Dusheiko G. Occult hepatitis B virus infection does not affect liver histology or response to therapy with interferon alpha and ribavirin in intravenous drug users with chronic hepatitis C. J Clin Virol. 2004;29:160-166. [PMID: 14962784 DOI: 10.1016/s1386-6532(03)00117-3] [Cited by in Crossref: 42] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
184 Onoe T, Tahara H, Tanaka Y, Ohdan H. Prophylactic managements of hepatitis B viral infection in liver transplantation. World J Gastroenterol 2016; 22(1): 165-175 [PMID: 26755868 DOI: 10.3748/wjg.v22.i1.165] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
185 Scuderi V, Ceriello A, Santaniello W, Aragiusto G, Romano M, Migliaccio C, Calise F. Hepatitis B prophylaxis in hepatitis B-negative recipients transplanted with donor grafts positive for hepatitis B core antibodies. Transplant Proc. 2011;43:271-273. [PMID: 21335203 DOI: 10.1016/j.transproceed.2010.09.100] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
186 Gallegos-Orozco JF, Vargas HE. Should antihepatitis B virus core positive or antihepatitis C virus core positive subjects be accepted as organ donors for liver transplantation? J Clin Gastroenterol 2007;41:66-74. [PMID: 17198068 DOI: 10.1097/01.mcg.0000225636.60404.bf] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
187 Raimondo G, Navarra G, Mondello S, Costantino L, Colloredo G, Cucinotta E, Di Vita G, Scisca C, Squadrito G, Pollicino T. Occult hepatitis B virus in liver tissue of individuals without hepatic disease. J Hepatol. 2008;48:743-746. [PMID: 18314221 DOI: 10.1016/j.jhep.2008.01.023] [Cited by in Crossref: 129] [Cited by in F6Publishing: 131] [Article Influence: 9.2] [Reference Citation Analysis]
188 Angelico M, Nardi A, Marianelli T, Caccamo L, Romagnoli R, Tisone G, Pinna AD, Avolio AW, Fagiuoli S, Burra P, Strazzabosco M, Costa AN; Liver Match Investigators. Hepatitis B-core antibody positive donors in liver transplantation and their impact on graft survival: evidence from the Liver Match cohort study. J Hepatol. 2013;58:715-723. [PMID: 23201239 DOI: 10.1016/j.jhep.2012.11.025] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 3.2] [Reference Citation Analysis]
189 Bárcena Marugán R, García-Hoz F, Vázquez Romero M, Nash R, Mateos M, González Alonso R, García González M, García Plaza A. Prevention of de novo hepatitis B infection in liver allograft recipients with previous hepatitis B infection or hepatitis B vaccination. Am J Gastroenterol 2002;97:2398-401. [PMID: 12358263 DOI: 10.1111/j.1572-0241.2002.05994.x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 1.0] [Reference Citation Analysis]
190 Kim JM, Choe BH, Chu MA, Cho SM. [Comparison of lamivudine-induced HBsAg loss rate according to age in children with chronic hepatitis B]. Korean J Hepatol. 2009;15:168-178. [PMID: 19581769 DOI: 10.3350/kjhep.2009.15.2.168] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
191 Yang YT, Huang AL, Zhao Y. The prevalence of hepatitis B core antibody in vaccinated Chinese children: A hospital-based study. Vaccine 2019;37:458-63. [PMID: 30527659 DOI: 10.1016/j.vaccine.2018.11.067] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
192 Uetake S, Yamauchi M, Itoh S, Kawashima O, Takeda K, Ohata M. Analysis of risk factors for hepatocellular carcinoma in patients with HBs antigen- and anti-HCV antibody-negative alcoholic cirrhosis: clinical significance of prior hepatitis B virus infection. Alcohol Clin Exp Res. 2003;27:47S-51S. [PMID: 12960507 DOI: 10.1097/01.alc.0000079449.47468.b0] [Cited by in Crossref: 36] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
193 Koneru B, Fisher A, He Y, Klein KM, Skurnick J, Wilson DJ, de la Torre AN, Merchant A, Arora R, Samanta AK. Ischemic preconditioning in deceased donor liver transplantation: a prospective randomized clinical trial of safety and efficacy. Liver Transpl. 2005;11:196-202. [PMID: 15666380 DOI: 10.1002/lt.20315] [Cited by in Crossref: 99] [Cited by in F6Publishing: 93] [Article Influence: 5.8] [Reference Citation Analysis]
194 Rokuhara A, Tanaka E, Yagi S, Mizokami M, Hashikura Y, Kawasaki S, Kiyosawa K. De novo infection of hepatitis B virus in patients with orthotopic liver transplantation: Analysis by determining complete sequence of the genome. J Med Virol 2000;62:471-8. [DOI: 10.1002/1096-9071(200012)62:4<471::aid-jmv12>3.0.co;2-x] [Cited by in Crossref: 33] [Article Influence: 1.5] [Reference Citation Analysis]
195 Muñoz S. Use of hepatitis B core antibody–positive donors for liver transplantation. Liver Transplantation 2002;8:S82-7. [DOI: 10.1053/jlts.2002.35783] [Cited by in Crossref: 63] [Cited by in F6Publishing: 59] [Article Influence: 3.2] [Reference Citation Analysis]
196 Roque-Afonso AM, Feray C, Samuel D, Simoneau D, Roche B, Emile JF, Gigou M, Shouval D, Dussaix E. Antibodies to hepatitis B surface antigen prevent viral reactivation in recipients of liver grafts from anti-HBC positive donors. Gut 2002;50:95-9. [PMID: 11772974 DOI: 10.1136/gut.50.1.95] [Cited by in Crossref: 94] [Cited by in F6Publishing: 88] [Article Influence: 4.7] [Reference Citation Analysis]
197 Chan AT, Chung RT. Hepatitis in the organ transplant patient: . Current Opinion in Organ Transplantation 2001;6:295-300. [DOI: 10.1097/00075200-200112000-00004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
198 Baltz AC, Trotter JF. Living donor liver transplantation and hepatitis C. Clinics in Liver Disease 2003;7:651-65. [DOI: 10.1016/s1089-3261(03)00058-8] [Cited by in Crossref: 21] [Cited by in F6Publishing: 3] [Article Influence: 1.1] [Reference Citation Analysis]
199 Niu Y, Chen X, Feng L, You H, Ren X, Liu H, Zheng J, Shen Z, Jia J. Anti-HBc–positive/HBsAg-negative liver donors pose a higher risk of occult HBV infection but do not cause severe histological damage in liver grafts. Clinics and Research in Hepatology and Gastroenterology 2014;38:475-80. [DOI: 10.1016/j.clinre.2014.03.016] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
200 Fábrega E. Liver transplantation with allografts from hepatitis B core antibody-positive donors: A new approach. Liver Transplantation 2003;9:916-20. [DOI: 10.1053/jlts.2003.50190] [Cited by in Crossref: 40] [Cited by in F6Publishing: 38] [Article Influence: 2.1] [Reference Citation Analysis]
201 Shintani Y, Yotsuyanagi H, Moriya K, Fujie H, Tsutsumi T, Takayama T, Makuuchi M, Kimura S, Koike K. The significance of hepatitis B virus DNA detected in hepatocellular carcinoma of patients with hepatitis C. Cancer 2000;88:2478-86. [DOI: 10.1002/1097-0142(20000601)88:11<2478::aid-cncr8>3.0.co;2-j] [Cited by in Crossref: 40] [Article Influence: 1.8] [Reference Citation Analysis]
202 Bain VG. Hepatitis B in transplantation. Transpl Infect Dis 2000;2:153-65. [PMID: 11429028 DOI: 10.1034/j.1399-3062.2000.020402.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.4] [Reference Citation Analysis]
203 Komori M, Yuki N, Nagaoka T, Yamashiro M, Mochizuki K, Kaneko A, Yamamoto K, Hikiji K, Kato M. Long-term clinical impact of occult hepatitis B virus infection in chronic hepatitis B patients. Journal of Hepatology 2001;35:798-804. [DOI: 10.1016/s0168-8278(01)00214-8] [Cited by in Crossref: 31] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
204 Rosen HR, Martin P. Viral hepatitis in the liver transplant recipient. Infect Dis Clin North Am 2000;14:761-84. [PMID: 10987119 DOI: 10.1016/s0891-5520(05)70130-6] [Cited by in Crossref: 24] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
205 Yu L, Koepsell T, Manhart L, Ioannou G. Survival after orthotopic liver transplantation: the impact of antibody against hepatitis B core antigen in the donor. Liver Transpl. 2009;15:1343-1350. [PMID: 19790164 DOI: 10.1002/lt.21788] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 2.4] [Reference Citation Analysis]
206 Yao FY, Bass NM, Nikolai B, Davern TJ, Kerlan R, Wu V, Ascher NL, Roberts JP. Liver transplantation for hepatocellular carcinoma: analysis of survival according to the intention-to-treat principle and dropout from the waiting list. Liver Transpl. 2002;8:873-883. [PMID: 12360427 DOI: 10.1053/jlts.2002.34923] [Cited by in Crossref: 291] [Cited by in F6Publishing: 279] [Article Influence: 15.3] [Reference Citation Analysis]
207 Ohno Y, Mita A, Ikegami T, Masuda Y, Urata K, Nakazawa Y, Kobayashi A, Miyagawa S. Successful active immunization using a hepatitis B virus vaccination protocol for a recipient with hepatitis B core antibody-positive liver graft. Transplant Proc. 2014;46:721-725. [PMID: 24767333 DOI: 10.1016/j.transproceed.2013.12.005] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
208 Yano Y, Yamashita F, Fukumori K, Kiyama M, Sumie S, Iwanaga K, Kuroki S, Kato O, Kiyomatsu K, Hirose N, Yamamoto H, Tanaka M, Sata M. Anti-HBc in Hepatocellular Carcinoma Without HBsAg, HBV DNA, Anti-HCV, and HCV RNA: . Journal of Clinical Gastroenterology 2000;30:213. [DOI: 10.1097/00004836-200003000-00019] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
209 Wang SH, Loh PY, Lin TL, Lin LM, Li WF, Lin YH, Lin CC, Chen CL. Active immunization for prevention of De novo hepatitis B virus infection after adult living donor liver transplantation with a hepatitis B core antigen-positive graft. Liver Transpl. 2017;23:1266-1272. [PMID: 28691231 DOI: 10.1002/lt.24814] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 6.0] [Reference Citation Analysis]
210 Wang Q, Klenerman P, Semmo N. Significance of anti-HBc alone serological status in clinical practice. The Lancet Gastroenterology & Hepatology 2017;2:123-34. [DOI: 10.1016/s2468-1253(16)30076-0] [Cited by in Crossref: 21] [Cited by in F6Publishing: 4] [Article Influence: 4.2] [Reference Citation Analysis]
211 Zhou K, Zhou S. Risk of disease transmission in an expanded donor population: the potential of hepatitis B virus donors. Curr Opin Organ Transplant 2020;25:631-9. [PMID: 33027191 DOI: 10.1097/MOT.0000000000000810] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
212 Pinney SP, Cheema FH, Hammond K, Chen JM, Edwards NM, Mancini D. Acceptable recipient outcomes with the use of hearts from donors with hepatitis-B core antibodies. The Journal of Heart and Lung Transplantation 2005;24:34-7. [DOI: 10.1016/j.healun.2003.09.036] [Cited by in Crossref: 28] [Cited by in F6Publishing: 20] [Article Influence: 1.6] [Reference Citation Analysis]
213 Makvandi M. Update on occult hepatitis B virus infection. World J Gastroenterol 2016; 22(39): 8720-8734 [PMID: 27818588 DOI: 10.3748/wjg.v22.i39.8720] [Cited by in CrossRef: 72] [Cited by in F6Publishing: 62] [Article Influence: 12.0] [Reference Citation Analysis]
214 Castells L, Esteban R. Hepatitis B vaccination in liver transplant candidates. Eur J Gastroenterol Hepatol. 2001;13:359-361. [PMID: 11338062 DOI: 10.1097/00042737-200104000-00009] [Cited by in Crossref: 26] [Cited by in F6Publishing: 20] [Article Influence: 1.2] [Reference Citation Analysis]
215 Hennig H, Puchta I, Luhm J, Schlenke P, Goerg S, Kirchner H. Frequency and load of hepatitis B virus DNA in first-time blood donors with antibodies to hepatitis B core antigen. Blood. 2002;100:2637-2641. [PMID: 12239179 DOI: 10.1182/blood-2002-03-0798] [Cited by in Crossref: 80] [Cited by in F6Publishing: 82] [Article Influence: 4.0] [Reference Citation Analysis]
216 Liu C, Chen D, Chen P. Epidemiology of HBV infection in Asian blood donors: Emphasis on occult HBV infection and the role of NAT. Journal of Clinical Virology 2006;36:S33-44. [DOI: 10.1016/s1386-6532(06)80007-7] [Cited by in Crossref: 72] [Cited by in F6Publishing: 25] [Article Influence: 4.5] [Reference Citation Analysis]
217 Skagen CL, Jou JH, Said A. Risk of de novo hepatitis in liver recipients from hepatitis-B core antibody-positive grafts - a systematic analysis. Clin Transplant. 2011;25:E243-E249. [PMID: 21323735 DOI: 10.1111/j.1399-0012.2011.01409.x] [Cited by in Crossref: 55] [Cited by in F6Publishing: 44] [Article Influence: 5.0] [Reference Citation Analysis]
218 Hosenpud JD, Pamidi SR, Fiol BS, Cinquegrani MP, Keck BM. Outcomes in patients who are hepatitis B surface antigen–positive before transplantation: an analysis and study using the joint ISHLT/UNOS thoracic registry. The Journal of Heart and Lung Transplantation 2000;19:781-5. [DOI: 10.1016/s1053-2498(00)00142-x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 2] [Article Influence: 1.1] [Reference Citation Analysis]
219 Shitrit AB, Kramer MR, Bakal I, Morali G, Ben Ari Z, Shitrit D. Lamivudine prophylaxis for hepatitis B virus infection after lung transplantation. Ann Thorac Surg 2006;81:1851-2. [PMID: 16631684 DOI: 10.1016/j.athoracsur.2005.12.026] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 1.3] [Reference Citation Analysis]
220 Urbani S, Fagnoni F, Missale G, Franchini M. The role of anti-core antibody response in the detection of occult hepatitis B virus infection. Clin Chem Lab Med. 2010;48:23-29. [PMID: 19919328 DOI: 10.1515/cclm.2010.002] [Cited by in Crossref: 32] [Cited by in F6Publishing: 22] [Article Influence: 2.7] [Reference Citation Analysis]
221 Chamorro C, Aparicio M. Influence of HBcAb positivity in the organ donor in heart transplantation. Med Intensiva 2012;36:563-70. [PMID: 22440791 DOI: 10.1016/j.medin.2012.01.011] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
222 Raimondo G, Balsano C, Craxì A, Farinati F, Levrero M, Mondelli M, Pollicino T, Squadrito G, Tiribelli C. Occult hepatitis B virus infection. Digestive and Liver Disease 2000;32:822-6. [DOI: 10.1016/s1590-8658(00)80362-x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
223 Fallahzadeh MA, Trotter JF. An Experiment of Nature: HBV-naive Recipients Receiving Liver Grafts With HBV Core Antibody-positive Donors Without Antiviral Prophylaxis. Transplantation 2020;104:e245-6. [PMID: 32732858 DOI: 10.1097/TP.0000000000003233] [Reference Citation Analysis]
224 Larghi A, Leffler D, Frucht H, Rubin M, Semrad CE, Lefkowitch JH, Worman HJ. Hepatitis B Virus Reactivation After Kidney Transplantation and New Onset Lymphoma: . Journal of Clinical Gastroenterology 2003;36:276-80. [DOI: 10.1097/00004836-200303000-00018] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.5] [Reference Citation Analysis]
225 Lacaille F, Sokal E. Living-Related Liver Transplantation: . Journal of Pediatric Gastroenterology and Nutrition 2001;33:431-8. [DOI: 10.1097/00005176-200110000-00002] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
226 Liang TJ. Hepatitis B: the virus and disease. Hepatology. 2009;49:S13-S21. [PMID: 19399811 DOI: 10.1002/hep.22881] [Cited by in Crossref: 426] [Cited by in F6Publishing: 383] [Article Influence: 32.8] [Reference Citation Analysis]
227 Souza LO, Perez RM, Carvalho-filho RJ, Matos CA, Moutinho RS, Silva IS, Medina-pestana JO, Silva AE, Ferraz ML. Unexpected distribution of Hepatitis B genotypes in patients with kidney disease: Comparison with immunocompetent subjects. J Med Virol 2012;84:1548-52. [DOI: 10.1002/jmv.23357] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
228 Hu K. Occult hepatitis B virus infection and its clinical implications. J Viral Hepat 2002;9:243-57. [DOI: 10.1046/j.1365-2893.2002.00344.x] [Cited by in Crossref: 204] [Cited by in F6Publishing: 202] [Article Influence: 10.2] [Reference Citation Analysis]
229 Burton JR Jr, Shaw-Stiffel TA. Use of hepatitis B core antibody-positive donors in recipients without evidence of hepatitis B infection: a survey of current practice in the United States. Liver Transpl. 2003;9:837-842. [PMID: 12884197 DOI: 10.1053/jlts.2003.50157] [Cited by in Crossref: 39] [Cited by in F6Publishing: 38] [Article Influence: 2.1] [Reference Citation Analysis]
230 Ikegami T, Yoshizumi T, Kawasaki J, Shimagaki T, Uchiyama H, Soejima Y, Maehara Y. Hepatocellular carcinoma developed in a living donor after left lobe donation: a case for caution. Hepatol Res 2017;47:715-8. [PMID: 27488094 DOI: 10.1111/hepr.12786] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
231 Loreno M, Bo P, Senzolo M, Cillo U, Naoumov N, Burra P. Successful pregnancy in a liver transplant recipient treated with lamivudine for de novo hepatitis B in the graft. Transpl Int. 2005;17:730-734. [PMID: 15717218 DOI: 10.1007/s00147-004-0785-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
232 Park JB, Kwon CH, Lee KW, Choi GS, Kim DJ, Seo JM, Kim SJ, Joh JW, Lee SK. Hepatitis B virus vaccine switch program for prevention of de novo hepatitis B virus infection in pediatric patients. Transpl Int. 2008;21:346-352. [PMID: 18208419 DOI: 10.1111/j.1432-2277.2007.00618.x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 1.4] [Reference Citation Analysis]
233 Chan HL. Changing scene in hepatitis B serology interpretation. Hospital Medicine 2002;63:16-9. [DOI: 10.12968/hosp.2002.63.1.1719] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 0.7] [Reference Citation Analysis]
234 Engler SH, Sauer PW, Golling M, Klar EA, Benz C, Stremmel W, Kallinowski B. Immunogenicity of two accelerated hepatitis B vaccination protocols in liver transplant candidates. Eur J Gastroenterol Hepatol. 2001;13:363-367. [PMID: 11338063 DOI: 10.1097/00042737-200104000-00010] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 1.4] [Reference Citation Analysis]
235 Adil B, Fatih O, Volkan I, Bora B, Veysel E, Koray K, Cemalettin K, Burak I, Sezai Y. Hepatitis B Virus and Hepatitis D Virus Recurrence in Patients Undergoing Liver Transplantation for Hepatitis B Virus and Hepatitis B Virus Plus Hepatitis D Virus. Transplant Proc. 2016;48:2119-2123. [PMID: 27569956 DOI: 10.1016/j.transproceed.2016.02.076] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
236 Manzarbeitia C, Reich DJ, Ortiz JA, Rothstein KD, Araya VR, Munoz SJ. Safe use of livers from donors with positive hepatitis B core antibody. Liver Transpl. 2002;8:556-561. [PMID: 12037788 DOI: 10.1053/jlts.2002.33451] [Cited by in Crossref: 72] [Cited by in F6Publishing: 69] [Article Influence: 3.6] [Reference Citation Analysis]
237 Bronowicki JP, Abdelmouttaleb I, Peyrin-Biroulet L, Venard V, Khiri H, Chabi N, Amouzou EK, Barraud H, Halfon P, Sanni A. Methylenetetrahydrofolate reductase 677 T allele protects against persistent HBV infection in West Africa. J Hepatol. 2008;48:532-539. [PMID: 18222012 DOI: 10.1016/j.jhep.2007.11.017] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.4] [Reference Citation Analysis]
238 Hicks LK, Lien K, Chan KK. ASCO Provisional Clinical Opinion for Hepatitis B Virus Screening Before Cancer Therapy: Are These the Right Tests in the Right Patients? J Oncol Pract 2015;11:e490-4. [PMID: 26188049 DOI: 10.1200/JOP.2015.004945] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
239 Lok AS, Heathcote EJ, Hoofnagle JH. Management of hepatitis B: 2000--summary of a workshop. Gastroenterology. 2001;120:1828-1853. [PMID: 11375963 DOI: 10.1053/gast.2001.24839] [Cited by in Crossref: 522] [Cited by in F6Publishing: 456] [Article Influence: 24.9] [Reference Citation Analysis]
240 Samuel D, Forns X, Berenguer M, Trautwein C, Burroughs A, Rizzetto M, Trepo C. Report of the Monothematic EASL Conference on Liver Transplantation for Viral Hepatitis. Journal of Hepatology 2006;45:127-43. [DOI: 10.1016/j.jhep.2006.05.001] [Cited by in Crossref: 129] [Cited by in F6Publishing: 110] [Article Influence: 8.1] [Reference Citation Analysis]
241 Avelino-Silva VI, D’Albuquerque LA, Bonazzi PR, Song AT, Miraglia JL, De Brito Neves A, Abdala E. Liver transplant from Anti-HBc-positive, HBsAg-negative donor into HBsAg-negative recipient: is it safe? A systematic review of the literature. Clin Transplant. 2010;24:735-746. [PMID: 20438579 DOI: 10.1111/j.1399-0012.2010.01254.x] [Cited by in Crossref: 34] [Cited by in F6Publishing: 28] [Article Influence: 3.1] [Reference Citation Analysis]
242 Prieto M. De novo hepatitis B after liver transplantation from hepatitis B core antibody—Positive donors in an area with high prevalence of anti-HBc positivity in the donor population. Liver Transplantation 2001;7:51-8. [DOI: 10.1053/jlts.2001.20786] [Cited by in Crossref: 154] [Cited by in F6Publishing: 133] [Article Influence: 7.3] [Reference Citation Analysis]
243 Pan JJ, Thosani N, Machicao VI, Fallon MB. Current use of hepatitis B immune globulin for prevention of de novo hepatitis B in recipients receiving anti-HBc-positive livers. Hepatol Int 2011;5:635-43. [PMID: 21484133 DOI: 10.1007/s12072-010-9250-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
244 Brock GN, Mostajabi F, Ferguson N, Carrubba CJ, Eng M, Buell JF, Marvin MR. Prophylaxis against de novo hepatitis B for liver transplantation utilizing hep B core (+) donors: does hepatitis B immunoglobulin provide a survival advantage? Transpl Int. 2011;24:570-581. [PMID: 21401727 DOI: 10.1111/j.1432-2277.2011.01236.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
245 Prakoso E, Strasser SI, Koorey DJ, Verran D, McCaughan GW. Long-term lamivudine monotherapy prevents development of hepatitis B virus infection in hepatitis B surface-antigen negative liver transplant recipients from hepatitis B core-antibody-positive donors. Clin Transplant. 2006;20:369-373. [PMID: 16824156 DOI: 10.1111/j.1399-0012.2006.00495.x] [Cited by in Crossref: 37] [Cited by in F6Publishing: 36] [Article Influence: 2.3] [Reference Citation Analysis]
246 Kim H, Choi J. Prophylaxis for Hepatitis B Core Antibody-Positive Donors after Liver Transplantation. J Korean Soc Transplant 2010;24:73. [DOI: 10.4285/jkstn.2010.24.2.73] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
247 Chung RT, Feng S, Delmonico FL. Approach to the management of allograft recipients following the detection of hepatitis B virus in the prospective organ donor. Am J Transplant. 2001;1:185-191. [PMID: 12099368 DOI: 10.1034/j.1600-6143.2001.10214.x] [Cited by in Crossref: 69] [Cited by in F6Publishing: 45] [Article Influence: 3.5] [Reference Citation Analysis]
248 Tan HH, Martin P. Management of end-stage liver disease in chronic hepatitis B. Clin Liver Dis. 2010;14:477-493. [PMID: 20638026 DOI: 10.1016/j.cld.2010.05.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
249 MacConmara MP, Vachharajani N, Wellen JR, Anderson CD, Lowell JA, Shenoy S, Chapman WC, Doyle MB. Utilization of hepatitis B core antibody-positive donor liver grafts. HPB (Oxford). 2012;14:42-48. [PMID: 22151450 DOI: 10.1111/j.1477-2574.2001.00399.x] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
250 Filippidis P, Vionnet J, Manuel O, Mombelli M. Prevention of viral infections in solid organ transplant recipients in the era of COVID-19: a narrative review. Expert Rev Anti Infect Ther 2021;:1-18. [PMID: 34854329 DOI: 10.1080/14787210.2022.2013808] [Reference Citation Analysis]
251 John S, Andersson KL, Kotton CN, Hertl M, Markmann JF, Cosimi AB, Chung RT. Prophylaxis of hepatitis B infection in solid organ transplant recipients. Therap Adv Gastroenterol 2013;6:309-19. [PMID: 23814610 DOI: 10.1177/1756283X13487942] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 1.1] [Reference Citation Analysis]
252 Lee T, Yang JJ, Eom J, Kwon S, Park BG, Hwang SH, Oh HB. A single-center, single-blind study to evaluate the clinical sensitivity, specificity, and agreement between Elecsys Anti-HBc II and Elecsys Anti-HBc in a Korean population. J Clin Virol 2018;109:41-4. [PMID: 30419551 DOI: 10.1016/j.jcv.2018.10.009] [Reference Citation Analysis]
253 Kim KD, Lee JE, Kim JM, Lee O, Hwang NY, Rhu J, Choi GS, Kim K, Joh JW. Cost-effectiveness and long-term outcomes of liver transplantation using hepatitis B core antibody-positive grafts with hepatitis B immunoglobulin prophylaxis in Korea. Clin Mol Hepatol 2021;27:603-15. [PMID: 34492755 DOI: 10.3350/cmh.2021.0137] [Reference Citation Analysis]
254 Yano Y, Yamashita F, Sumie S, Kuwaki K, Yamamoto H, Toyoda N, Ando E, Tanaka M, Sata M. Clinical significance of antibody against hepatitis B virus core antigen in patients with hepatitis C virus-related hepatocellular carcinoma. Liver Int 2003;23:227-31. [PMID: 12895261 DOI: 10.1034/j.1600-0676.2003.00831.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
255 Smith H, Gibbs P. HEPATITIS B, THE HIDDEN DANGER IN CADAVERIC ORGAN DONORS: . Transplantation 2000;69:457. [DOI: 10.1097/00007890-200002150-00032] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
256 Ustün C, Idilman R, Gürman G, Ozcan M, Akyol G, Akan H, Ilhan O, Beksaç M, Uysal A, Konuk N, Karayalçin S, Poyraz A, Van Thiel D, Koç H. Hematopoietic stem cell transplantation from non-replicative hepatitis B virus carriers is safe. J Hepatol 1999;31:202-9. [PMID: 10453930 DOI: 10.1016/s0168-8278(99)80214-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
257 Nery J, Gedaly R, Vianna R, Berho M, Weppler D, Levi D, Kato T, Khan F, Pinna A, Schiff E, Tzakis A. Are liver grafts from hepatitis B surface antigen negative/anti-hepatitis B core antibody positive donors suitable for transplantation? Transplantation Proceedings 2001;33:1521-2. [DOI: 10.1016/s0041-1345(00)02580-x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
258 Khemichian S, Kahn J, Terrault NA. Use of Hepatitis B Virus-Positive Organs in Organ Transplantation. Clin Liver Dis 2021;25:841-57. [PMID: 34593157 DOI: 10.1016/j.cld.2021.06.009] [Reference Citation Analysis]
259 Le Mire MF, Miller DS, Foster WK, Burrell CJ, Jilbert AR. Covalently closed circular DNA is the predominant form of duck hepatitis B virus DNA that persists following transient infection. J Virol. 2005;79:12242-12252. [PMID: 16160150 DOI: 10.1128/jvi.79.19.12242-12252.2005] [Cited by in Crossref: 31] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
260 Shim J, Kim BH, Kim NH, Dong SH, Kim HJ, Chang YW, Lee JI, Chang R. Clinical features of HBsAg-negative but anti-HBc-positive hepatocellular carcinoma in a hepatitis B virus endemic area. J Gastroenterol Hepatol 2005;20:746-51. [PMID: 15853989 DOI: 10.1111/j.1440-1746.2005.03747.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
261 Marciano S, Gaite LA, Bisignano L, Descalzi VI, Yantorno S, Mendizabal M, Silva MO, Anders M, Orozco OF, Traverso R. Use of liver grafts from anti-hepatitis B core-positive donors: a multicenter study in Argentina. Transplant Proc. 2013;45:1331-1334. [PMID: 23726565 DOI: 10.1016/j.transproceed.2012.12.016] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
262 Saab S, Waterman B, Chi AC, Tong MJ. Comparison of different immunoprophylaxis regimens after liver transplantation with hepatitis B core antibody-positive donors: a systematic review. Liver Transpl. 2010;16:300-307. [PMID: 20209589 DOI: 10.1002/lt.21998] [Cited by in Crossref: 96] [Cited by in F6Publishing: 71] [Article Influence: 8.0] [Reference Citation Analysis]
263 Verna EC, Brown RS. Hepatitis C and Liver Transplantation: Enhancing Outcomes and Should Patients Be Retransplanted. Clinics in Liver Disease 2008;12:637-59. [DOI: 10.1016/j.cld.2008.03.010] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 2.1] [Reference Citation Analysis]
264 Mulrooney-Cousins PM, Michalak TI. Repeated passage of wild-type woodchuck hepatitis virus in lymphoid cells does not generate cell type-specific variants or alter virus infectivity. J Virol 2008;82:7540-50. [PMID: 18495768 DOI: 10.1128/JVI.00405-08] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
265 Soejima Y, Shimada M, Taketomi A, Yoshizumi T, Uchiyama H, Ikegami T, Nakamuta M, Maehara Y. Successful living donor liver transplantation using a graft from a hepatitis B surface antigen-positive donor. Liver Int. 2007;27:1282-1286. [PMID: 17919241 DOI: 10.1111/j.1478-3231.2007.01528.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
266 Boyacioğlu S, Arslan H, Demirhan B, Gür G, Turan M, Haberal M. Is there risk of transmitting hepatitis B virus in accepting hepatitis B core antibody-positive donors for living related liver transplantation? Transplantation Proceedings 2001;33:2802-3. [DOI: 10.1016/s0041-1345(01)02196-0] [Cited by in Crossref: 7] [Article Influence: 0.3] [Reference Citation Analysis]
267 Kwak MS, Kim YJ. Occult hepatitis B virus infection. World J Hepatol 2014; 6(12): 860-869 [PMID: 25544873 DOI: 10.4254/wjh.v6.i12.860] [Cited by in Crossref: 46] [Cited by in F6Publishing: 42] [Article Influence: 5.8] [Reference Citation Analysis]
268 Zervou EK, Dalekos GN, Boumba DS, Tsianos EV. Value of anti-HBc screening of blood donors for prevention of HBV infection: results of a 3-year prospective study in Northwestern Greece. Transfusion. 2001;41:652-658. [PMID: 11346702 DOI: 10.1046/j.1537-2995.2001.41050652.x] [Cited by in Crossref: 56] [Cited by in F6Publishing: 57] [Article Influence: 2.7] [Reference Citation Analysis]
269 Yen RD, Bonatti H, Mendez J, Aranda-michel J, Satyanarayana R, Dickson RC. Case Report of Lamivudine-Resistant Hepatitis B Virus Infection Post Liver Transplantation from a Hepatitis B Core Antibody Donor: De Novo HB Infection from an HB Core Antibody Donor . American Journal of Transplantation 2006;6:1077-83. [DOI: 10.1111/j.1600-6143.2006.01313.x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 2.1] [Reference Citation Analysis]
270 Takaki A, Yagi T, Yamamoto K. Contradictory immune response in post liver transplantation hepatitis B and C. Int J Inflam 2014;2014:814760. [PMID: 25215259 DOI: 10.1155/2014/814760] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
271 Ho JK, Harrigan PR, Sherlock CH, Steinbrecher UP, Erb SR, Mo T, Chung SW, Buczkowski AK, Intaraprasong P, Scudamore CH, Yoshida EM. Utilization of a Liver Allograft from a Hepatitis B Surface Antigen Positive Donor. Transplantation 2006;81:129-31. [DOI: 10.1097/01.tp.0000191946.49884.40] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
272 Vierling JM. Management of HBV Infection in Liver Transplantation Patients. Int J Med Sci 2005;2:41-9. [PMID: 15968339 DOI: 10.7150/ijms.2.41] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 0.8] [Reference Citation Analysis]
273 Natov S, Pereira B. Transmission of viral hepatitis by kidney transplantation: donor evaluation and transplant policies (Part 1: hepatitis B virus): Viral hepatitis B and kidney donor evaluation. Transplant Infectious Disease 2002;4:117-23. [DOI: 10.1034/j.1399-3062.2002.t01-1-01002.x] [Cited by in Crossref: 37] [Cited by in F6Publishing: 30] [Article Influence: 1.9] [Reference Citation Analysis]
274 Suehiro T, Shimada M, Kishikawa K, Shimura T, Soejima Y, Yoshizumi T, Hashimoto K, Mochida Y, Maehara Y, Kuwano H. Prevention of hepatitis B virus infection from hepatitis B core antibody-positive donor graft using hepatitis B immune globulin and lamivudine in living donor liver transplantation. Liver Int. 2005;25:1169-1174. [PMID: 16343068 DOI: 10.1111/j.1478-3231.2005.01165.x] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 1.7] [Reference Citation Analysis]
275 Hwang JP, Fisch MJ, Lok AS, Zhang H, Vierling JM, Suarez-Almazor ME. Trends in hepatitis B virus screening at the onset of chemotherapy in a large US cancer center. BMC Cancer 2013;13:534. [PMID: 24209764 DOI: 10.1186/1471-2407-13-534] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 2.4] [Reference Citation Analysis]
276 Miédougé M, Rostaing L, Mansuy JM, Sandres-sauné K, Boudet F, Izopet J. Screening for Hepatitis B Virus DNA in Serum of Organ Donors and Renal Transplant Recipients. Eur J Clin Microbiol Infect Dis 2003;22:246-8. [DOI: 10.1007/s10096-003-0889-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
277 Villamil I, González-quintela A, Aguilera A, Tomé S, Otero E, Castroagudín F, Varo E. Truly de novo Hepatitis B After Liver Transplantation. Am J Gastroenterol 2004;99:767-8. [DOI: 10.1111/j.1572-0241.2004.04126.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
278 Takaki A, Yasunaka T, Yagi T. Molecular Mechanisms to Control Post-Transplantation Hepatitis B Recurrence. Int J Mol Sci 2015;16:17494-513. [PMID: 26263973 DOI: 10.3390/ijms160817494] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
279 Crespo J, Fábrega E, Casafont F, Rivero M, de las Heras G, de la Peña J, de la Cruz F, Pons-romero F. Severe clinical course of de novo hepatitis B infection after liver transplantation. Liver Transpl 1999;5:175-83. [DOI: 10.1002/lt.500050301] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 2.2] [Reference Citation Analysis]
280 Lin CC, Yong CC, Chen CL. Active vaccination to prevent de novo hepatitis B virus infection in liver transplantation. World J Gastroenterol 2015; 21(39): 11112-11117 [PMID: 26494965 DOI: 10.3748/wjg.v21.i39.11112] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
281 Verna EC. Hepatitis viruses and liver transplantation: evolving trends in antiviral management. Clin Liver Dis. 2014;18:575-601. [PMID: 25017077 DOI: 10.1016/j.cld.2014.05.002] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
282 Yoshizawa A, Yamashiki N, Ueda Y, Kaido T, Okajima H, Marusawa H, Chiba T, Uemoto S. Long-term efficacy of hepatitis B vaccination as post-transplant prophylaxis in hepatitis B surface antigen (HBsAg) positive recipients and HBsAg negative recipients of anti-hepatitis B core positive grafts. Hepatol Res 2016;46:541-51. [PMID: 26348993 DOI: 10.1111/hepr.12586] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]